Hansoh Pharma H1 2025 Financial ReportHansoh PharmaHansoh Pharma’s 2025 interim report highlights strong growth, innovation-driven transformation, and a robust global pipeline, setting a new benchmark for Chinese biopharma.
Hansoh and Hengrui: A Pharmaceutical Power CoupleHengruiDiscover how Hansoh Pharmaceutical transformed from a generic drugmaker into a global innovator through aggressive R&D, strategic partnerships, and successful international launches like Almonertinib.
Regeneron Secures $2B Deal for Hansoh’s Obesity Drug Rivaling ZepboundRegeneronRegeneron signs a $2B deal with Hansoh Pharma for HS-20094, a GLP-1/GIP receptor agonist aimed at rivaling Eli Lilly’s Zepbound in the obesity market. The deal boosts Regeneron's obesity pipeline with late-stage drug access and new combo therapy potential.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
